William Holtz on Regulatory Balance in Peptide Market
June 23, 2026
The Wall Street Journal
Foley & Lardner LLP of counsel William Holtz was quoted in The Wall Street Journal’s article, “Businesses Are Taking Risks to Cash In on the Peptide Gold Rush,” examining the risks and regulatory challenges facing compounding pharmacies supplying peptides.
Holtz noted that compounding pharmacies are manufacturing previously restricted peptides “without explicit permission from FDA.”
He described the current regulatory landscape as a “delicate balance the federal government is trying to strike: navigating a regulatory process meant to keep consumers safe against the possibility that these experimental drugs could help people with certain conditions.”
(Subscription requried)
People
Related News
November 16, 2026
In the News
Foley's State Attorneys General Practice Featured Across Media for Takeaways on Midterm Results
Foley & Lardner LLP's State Attorneys General Practice garnered significant media coverage for perspective on the 2026 midterm results and what shifts businesses should be paying attention to as incoming state attorneys general prepare to assume office.
November 16, 2026
In the News
Foley COO Jen Patton Describes Firm’s AI-First Approach, Lessons for Companies at Milwaukee Business Journal AI Panel
Foley & Lardner LLP Chief Operating Officer Jen Patton shared how the firm is taking a practical, responsible approach to integrating AI alongside industry leaders at the Milwaukee Business Journal’s Real Intelligence About Artificial Intelligence panel.
November 13, 2026
In the News
Vanessa Miller Explores AI Opportunities and Risks in Automotive Manufacturing
Foley & Lardner LLP partner Vanessa Miller participated in the State of Automotive Manufacturing virtual event hosted by Manufacturing Dive and WardsAuto, examining the legal and operational implications of AI and advanced technology adoption in the automotive industry.